Axa
GNCA

Axa’s Genocea Biosciences, Inc. GNCA Stock Holding History

Axa’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-72,274
Closed -$844K – 1415
2017
Q3 		$844K Sell
72,274
-984
-1% -$37.3K ﹤0.01% 995
2017
Q2 		$3.06M Sell
73,258
-2,734
-4% -$132K 0.01% 706
2017
Q1 		$3.7M Buy
75,992
+167
+0.2% +$6.53K 0.02% 654
2016
Q4 		$2.5M Buy
75,825
+1,409
+2% +$46.4K 0.01% 720
2016
Q3 		$3.05M Buy
74,416
+21
+0% +$824 0.01% 664
2016
Q2 		$2.44M Buy
74,395
+1,023
+1% +$37.5K 0.01% 707
2016
Q1 		$4.54M Hold
73,372
– – 0.02% 585
2015
Q4 		$3.09M Sell
73,372
-1,542
-2% -$73.5K 0.01% 686
2015
Q3 		$4.11M Buy
74,914
+8,617
+13% +$855K 0.02% 621
2015
Q2 		$7.28M Hold
66,297
– – 0.03% 483
2015
Q1 		$6.29M Buy
66,297
+36,554
+123% +$2.58M 0.03% 523
2014
Q4 		$1.67M Buy
29,743
+8,907
+43% +$608K 0.01% 842
2014
Q3 		$1.51M Hold
20,836
– – 0.01% 820
2014
Q2 		$3.13M Hold
20,836
– – 0.01% 670
2014
Q1 		$3.03M Buy
+20,836
New +$2.55M 0.01% 651

Other funds holding GNCA

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Axa's GNCA Position: Q4 2017 in Review

Axa sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2017, closing a stake of 72,274 shares — an estimated $844K sold.

Axa first reported a position in GNCA in Q1 2014 and held it in 15 quarters. The position peaked at $7.28M in Q2 2015. 56 funds tracked by Wall St. Rank hold GNCA as of Q4 2017.

  • Axa reported no remaining Genocea Biosciences, Inc. position as of Q4 2017 after selling out during the quarter.
  • Axa sold 72,274 Genocea Biosciences, Inc. shares in Q4 2017, an estimated $844K.
  • Axa first reported a position in Genocea Biosciences, Inc. in Q1 2014 and held it in 15 quarters.
  • Axa's Genocea Biosciences, Inc. position peaked at $7.28M in Q2 2015.
  • 56 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2017.

Based on Axa's 13F filing for Q4 2017, filed 13 Feb 2018.